Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients

Inclusion Criteria: * Subjects diagnosed with recurrent malignant lymphoma, which express B7 and FasR and have either failed to respond to standard therapy, relapsed and for whom no standard therapy is available. * Measurable disease as measured by "Lugano" Classification. * A measurable node must have a longest diameter (LDi) greater than 1.5 cm. Measurable extranodal disease (eg, hepatic nodules) may be included in the six representative, measured lesions. A measurable extranodal lesion should have an LDi greater than 1.0 cm * Biopsy of tumor stains positive to cluster of differentiation 95 (CD95) and to Cluster of Differentiation 80 (CD80) or Cluster of Differentiation 86 (CD86) or both within the last 6 months. * If greater than 6 months , a fine-needle aspiration (FNA) should be performed * Men and Women age \> 18. * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 3. * Estimated life expectancy of at least 2 months. * Adequate liver function (serum bilirubin ≤2.0 mg/100 ml; alanine aminotransferase, aspartate aminotransferase ≤2× ULN). * Adequate renal function (serum creatinine ≤1.5 mg/100 ml or creatinine clearance ≥30 ml/min/1.73m2 as measured by Cockcroft -Gault / CKD (Chronic Kidney Disease)/EPI (Epidemiology Collaboration) formulas. * Platelet count ≥ 50,000 and an absolute neutrophil count (ANC) ≥ 1500 /mm3. * Women of child bearing potential practicing an acceptable method of birth control. * Understanding of study procedures and willingness to comply for the entire length of the study and to give written informed consent. Exclusion Criteria: * Other standard anti-neoplastic therapies are available. * Known Central Nervous System (CNS) lymphoma. * Chronic lymphocytic leukemia and autoimmunity leukemia. * Known hypersensitivity to the study drug or to any of its components. * Chronic heat failure (CHF) New-York heart association (NYHA) = Class IV. * Known Chronic Obstructive Pulmonary Disease (COPD) \> Stage 3 (Forced Expiratory Volume -(FEV1)\<50%, FEV1/Forced Vital Capacity (FVC)\<70%). * Chronic kidney disease (CKD) \>Stage 4 (subjects with known Filtration rate (FR)\<30 milliliter (mL)/min/1.73m2). * Cirrhosis (Child-Pugh Class C score). * Known hypersensitivity to drug components. * Prior chemotherapy within 3 weeks, nitrosureas within 6 weeks, therapeutic anticancer antibodies within 3 weeks, radio or toxin immunoconjugates within 10 weeks, radiation therapy within 3 weeks, or major surgery within 28 days of first dose of the study drug. * American Society for Cytotechnology (ASCT) and prior allogeneic stem cell transplantation (SCT)\< 12 weeks prior to first dose of the study drug. * Myelosuppressive treatment within 2-3 weeks of entering this study. Prednisone allowed. * Any other severe concurrent disease which in the judgment of the investigator would make the subject inappropriate for entry into this study. * Positive test for acquired immune deficiency syndrome (AIDS). * Any positive test for hepatitis B or hepatitis C virus (HBV or HCV) indicating acute or chronic infection (HBsAg, HBcAb total and anti-HCV Abs). * Presence of uncontrolled infection. * Evidence of active bleeding or bleeding susceptibility or medically significant hemorrhage within prior 30 days. * Coumadin therapy. * Pregnant or lactating. * Treatment with other investigational drugs within 14 days of start of this study. * Prisoners or subjects who are involuntarily incarcerated. * Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.